25
May

08:00 AM EDT

Medicinal Chemistry

Strategy Meeting East Coast USA 2022

The premier meeting for all East Coast USA Medicinal Chemistry professionals

Le Meridien Cambridge

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered.

Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say...

See the full agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Meet Our 2022 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Maneesh Pingle

Head – Discovery Business Development Sai Life Sciences Ltd

Victoria Steadman

Vice President of Business Development and Integrated Partnerships Sai Life Sciences Ltd

Lurong Pan

Founder and CEO Ainnocence

Norman Azoulay

Director, Scientific Products Excelra

Matthew Segall PhD

CEO Optibrium

Tamsin Mansley

Head of North American Operations Optibrium

Tamsin Mansley is Head of North American Operations at Optibrium Limited. She holds a PhD in Organic Chemistry from University of East Anglia in the UK and pursued Postdoctoral studies in the labs of Prof. Philip Magnus at University of Texas, Austin. Tamsin is an experienced drug discovery scientist, having worked as a medicinal chemist at Eli Lilly and UCB Research. 
It was here that she developed her passion for applying computational chemistry and predictive modelling approaches for compound selection and design. Her interests lie in coupling machine learning and artificial intelligence techniques with generative chemistry approaches to explore chemistry space and guide compound design. 
Tamsin joined Optibrium in 2015 to develop new opportunities across North America for Optibrium’s fully integrated, elegant software that guides drug discovery. She also leads the global Application Science team, supporting the company’s existing 
client base.

Whitney Smith

Director of Business Development Collaborative Drug Discovery

Whitney earned a PhD from UC Berkeley in 1996, developing a love for using computational and informatics tools to solve his in-the-lab chemistry challenges. Following roles at a number of Bay Area biotech startups as “the Med Chemist who also did computer stuff”, Whitney became a full-time Cheminformatics Scientist in 2003. A few years later he took a technical position at then-Accelrys (now BIOVIA), experiencing the industry from a new “vendor-side” perspective. In 2007, he transitioned to a sales role and has since held various regional and strategic sales positions at Accelrys, IDBS, Model N, and now Collaborative Dug Discovery. His responsibilities have included the sale and implementation of solutions across such highly diverse domains as cheminformatics, bioinformatics, GLP/GMP systems, business analytics, drug pricing, and revenue management. Whitney routinely engages with biotechs, big pharma, government, academic labs, and everyone in between to help solve their informatics, scientific, and business challenges.

Sandro Belvedere

Vice President, Chemistry Avicenna Biosciences, Inc.

Ivan Cornella-Taracido

VP, Translational Chemical Biology Roivant Discovery

Iván Cornella-Taracido is the Vice President of Translational Chemical Biology at Roivant Discovery. His team develops and leverages chemical biology and proteomics methods and workflows to support  the discovery organization and translational assessment of clinical opportunities for target selection,  biomarker identification, and indication expansion. In previous roles, at Cedilla Therapeutics, Merck, AstraZeneca, and Sanofi, Iván established and  managed chemical biology and proteomics teams, supporting target and drug discovery initiatives  across disease areas and modalities. Before Sanofi, at Novartis, he was a founding member of the NIBR  target identification and mode of action elucidation (TIDMoA) platform. Throughout his career, Iván has  also acted as consultant on target and drug discovery for a number of start-ups and biotech firms. Iván holds a Ph.D. in organic chemistry from the Universidade da Coruña, Spain, and earned an  Executive Certificate in innovation from MIT Sloan School of Management. He completed postdoctoral  work at the Institute of Chemistry & Cell Biology of Harvard Medical School (now the Broad Institute of  MIT and Harvard), as National Cancer Institute Initiative for Chemical Genetics Research Fellow, and at  the Boston College chemistry department. Iván volunteers as committee member for the Chemistry in Cancer Research section of the AACR, and as  ambassador for the non-profit organization SeedingLabs. He has been an invited speaker, organizer and  chair for numerous international conferences on drug discovery, phenotypic screening, target  identification, chemical biology and proteomics.

Paola Castaldi

VP, Chemical Biology & Proteomics LifeMine Therapeutics

Dario Doller

VP, Drug Discovery Lucy Therapeutics

Kenneth Duncan

VP, Chemistry Accent Therapeutics

Scott Edmondson

SVP, Head of Chemistry Nimbus Therapeutics

Dr. Scott Edmondson is Senior Vice President, Head of Chemistry at Nimbus Therapeutics. Before joining Nimbus, he served as the Director and Head of Boston Oncology Chemistry at AstraZeneca, where he led a team of over 45 internal chemists and 25 CRO chemists that executed on drug discovery programs in oncology from target validation through candidate discovery. While at AstraZeneca, Scott also co-led the Global Oncology PROTACs effort to help establish and grow this promising new modality. Dr. Edmondson began his career at Merck Research Laboratories where he worked on projects in the early discovery space through late-stage discovery and beyond. Over the course of his career, Scott has authored/co-authored over 55 publications, over 60 patents/patent applications and has led/contributed to teams that have delivered over a dozen clinical candidates and 2 marketed drugs. Dr. Edmondson received an undergraduate degree in chemistry from Cornell University followed by his Ph.D. from The Ohio State University in 1996 with Prof. Leo Paquette. He completed an NIH postdoctoral fellowship with Prof. Samuel Danishefsky at Columbia University prior to joining Merck.

Ivan Efremov

VP, Head of Medicinal Chemistry Fulcrum Therapeutics

Adam Gilbert

Senior Scientific Director, Design & Synthesis Sciences Pfizer

Adam Gilbert was born in New York City and raised in Chappaqua, NY in Westchester County. He majored in chemistry at Haverford College and graduated cum laude/with honors with a B.A. in chemistry.  He received his Ph.D. with Professor Thomas Katz at Columbia University in 1992 where he worked on preparing novel helical metallocene conductors and catalysts.  After a postdoc with Professor William Wulff at the University of Chicago where he worked on the total synthesis of the anticancer agent olivin and developing novel synthetic methodologies involving Fischer carbene complexes, he joined the Medical Research Division of American Cyanamid in Pearl River, NY which became Wyeth-Ayerst Research and finally Wyeth Research.
Adam joined the Pfizer in February 2010 as an Associate Research Fellow and a labhead in charge of the Experimental Design Chemistry (EDC) – a group that focused on key portfolio projects with challenging medicinal chemistry design issues including covalent inhibitors, allosteric GPCR modulators, and chemoproteomics. EDC helped drive candidate molecule discovery for programs in Rare Diseases, Neuroscience, and Immunology highlighted by PF-06651600 (ritlecitinib), a covalent JAK3/Tec inhibitor currently in Phase 2b/3 trials for Alopecia Areata.  Adam is currently a Senior Director in charge of Pfizer’s Design and Synthesis Sciences (DSS) Group.  DSS is a platform medchem group located in Pfizer’s Discovery Sciences Department in Groton, CT which helps drive key Pfizer initiatives such as protein degradation, DNA-encoded library chemistry and selection analysis, covalent inhibitor design, vaccine protein design, small molecule purification, and small molecule NMR.

Paul Greenspan

Senior Director, Discovery Chemistry Takeda

Richard Heidebrecht

Vice President and R&D Glycologix

Blaise Lippa

SVP, Molecular Discovery Morphic Therapeutics

Christine Loh

SVP Biology Nimbus Therapeutics

Jesus Medina

Research Fellow Arvinas

Ingo Mügge

Executive Director, Head of Modeling & Informatics Alkermes

Patrick Riley, PhD

SVP, AI Relay Therapeutics

Nunzio Sciammetta

Director, Discovery Chemistry Merck & Co Inc

Huafeng Xu

CTO Roivant Sciences

Lei Zhang

Head of Design, IM Medicinal Chemistry Pfizer

Lei Zhang received his B.S. in chemistry from Peking University in China and pursued graduate work at Stanford University with a research focus on novel methodology development and total synthesis of natural products.  After receiving his Ph.D. in 2002, Lei joined Pfizer laboratories as a medicinal chemist and worked in multiple therapeutic areas including neuroscience, oncology and internal medicine. He is currently a senior director of medicinal chemistry, leading the molecular design group of internal medicine medicinal chemistry, based at Cambridge, MA. During his tenure at Pfizer, Lei and his team have successfully delivered a number of clinical candidates for disorders with high unmet medical needs in the areas of CNS, immuno-oncology and metabolic diseases. Lei is also a recognized leader in novel positron emission tomography (PET) ligand discovery. He pioneered a set of PET ligand selection criteria and established a unique and effective industry/academic collaboration model, yielding a number of first-in-class PET ligands that have since been successfully validated in the clinic.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Drug Discovery Biology Strategy Meeting East Coast November 2023

Medicinal Chemistry

Strategy Meeting East Coast USA 2022

<img decoding="async" src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Become an official strategy meeting partner

Press play to hear what your colleagues had to say...

See the full agenda and facilitator line-up

Meet Our 2022 Facilitators

Maneesh Pingle

Victoria Steadman

Lurong Pan

Norman Azoulay

Matthew Segall PhD

Tamsin Mansley

Whitney Smith

Sandro Belvedere

Ivan Cornella-Taracido

Paola Castaldi

Dario Doller

Kenneth Duncan

Scott Edmondson

Ivan Efremov

Adam Gilbert

Paul Greenspan

Richard Heidebrecht

Blaise Lippa

Christine Loh

Jesus Medina

Ingo Mügge

Patrick Riley, PhD

Nunzio Sciammetta

Huafeng Xu

Lei Zhang

Our 2022 Thought Leader

Our 2022 Co-Hosts

Here To Help

Want to find out more?

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

Le Meridien Cambridge